A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...

Alumis is advancing ESK-001 for plaque psoriasis with phase 3 data expected in 2026. Read why ALMS stock is compelling yet ...

In cases involving unpredictable factors, such as most chemical reactions, pharmaceutical activity, and physiological ...

New Ohio law restricts transgender students’ access to school restrooms, 'bathroom bill' sparks outcry Ohio Governor Mike DeWine recently signed the "Protect All Students Act," effectively ...

November 28, 2024 • In an episode we first posted in January, we go to the West African country of Ghana. The Ghanaian government began encouraging people of African descent from around the ...